Clinical characteristics of patients with COVID-19 vaccine-related pneumonitis: a case series and literature review
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Pulmonary toxicities of coronavirus disease 2019 (COVID-19) vaccination are exceedingly rare. However, there are a few reported cases after mRNA vaccination, especially from Asian countries. The purpose of this study was to report the clinical characteristics of patients with COVID-19 vaccine-related pneumonitis (CV-P) and to review cases reported in the literature. Methods: We performed a prospective, observational case series analysis. Results: Eleven patients with a median age of 80 years were enrolled. Ten patients developed CV-P after BNT162b2-mRNA vaccination and one after ChAdOx1 nCoV-19 vaccination. We identified various patterns of CV-P, including transient infiltration, life-threatening acute respiratory distress syndrome, and aggravation of underlying interstitial lung disease. Most patients showed favorable outcomes with good responses to corticosteroid therapy. Conclusions: Identifying the mechanism of CV-P requires further investigation; however, radiological and laboratory findings in our case series support inflammatory dysregulation in the lung parenchyma after vaccination. Clinicians should consider CV-P in patients with atypical lung infiltration, no specific etiologies, and recent COVID-19 vaccination.
Abstract
Background/Aims: Pulmonary toxicities of coronavirus disease 2019 (COVID-19) vaccination are exceedingly rare. However, there are a few reported cases after mRNA vaccination, especially from Asian countries. The purpose of this study was to report the clinical characteristics of patients with COVID-19 vaccine-related pneumonitis (CV-P) and to review cases reported in the literature. Methods: We performed a prospective, observational case series analysis. Results: Eleven patients with a median age of 80 years were enrolled. Ten patients developed CV-P after BNT162b2-mRNA vaccination and one after ChAdOx1 nCoV-19 vaccination. We identified various patterns of CV-P, including transient infiltration, life-threatening acute respiratory distress syndrome, and aggravation of underlying interstitial lung disease. Most patients showed favorable outcomes with good responses to corticosteroid therapy. Conclusions: Identifying the mechanism of CV-P requires further investigation; however, radiological and laboratory findings in our case series support inflammatory dysregulation in the lung parenchyma after vaccination. Clinicians should consider CV-P in patients with atypical lung infiltration, no specific etiologies, and recent COVID-19 vaccination.
참고문헌 (34)
- Helfand BK, "The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019 : missing the target", JAMA Intern Med, 180, pp.1546~1549 (2020)
- Barda N, "Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting", N Engl J Med, 385, pp.1078~1090 (2021)
- Bozkurt B, "Myocarditis with COVID-19mRNA vaccines", Circulation, 144, pp.471~484 (2021)
- Huynh A, "Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia", Nature, 596, pp.565~569 (2021)
- Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1nCov-19 vaccination", N Engl J Med, 384, pp.2092~2101 (2021)
- Klok FA, "Vaccine-induced immune thrombotic thrombocytopenia", Lancet Haematol, 9, pp.e73~e80 (2022)
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
- Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARSCoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
- Miller E, "Rapid evaluation of the safety of COVID-19 vaccines : how well have we done?", Clin Microbiol Infect, 28, pp.477~478 (2022)
- Watanabe S, "Influenza vaccine-induced interstitial lung disease", Eur Respir J, 41, pp.474~477 (2013)
- Niebel D, "Cutaneous adverse reactions to COVID-19 vaccines: insights from an immuno-dermatological perspective", Vaccines(Basel), 9, pp.944~ (2021)
- Johkoh T, "Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors : a position paper from the Fleischner Society", Chest, 159, pp.1107~1125 (2021)
- Park JY, "COVID-19 vaccine-related interstitial lung disease : a case study", Thorax, 77, pp.102~104 (2022)
- Camus P, "Interstitial lung disease induced by drugs and radiation", Respiration, 71, pp.301~326 (2004)
- "Weekly analysis of adverse reactions after COVID-19 vaccination" (2022)[URL]
- "Canadian COVID-19 vaccination safety report" (2022)[URL]
- Ji Young Park, "Changes in respiratory virus infection trends during the COVID-19 pandemic in South Korea: the effectiveness of public health measures", The Korean Journal of Internal Medicine, 36(5), pp.1157~1168 (2021), 대한내과학회[DOI]
- Huh K, "Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic : a nationwide claims study", Thorax, 76, pp.939~941 (2021)
- Cagigi A, "Immune responses induced by mRNA vaccination in mice, monkeys and humans", Vaccines(Basel), 9, pp.61~ (2021)
- Vojdani A, "Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens : implications for autoimmune diseases", Front Immunol, 11, pp.617089~ (2021)
- Tan EM, "Range of antinuclear antibodies in"healthy"individuals", Arthritis Rheum, 40, pp.1601~1611 (1997)
- Rijkers GT, "Antigen presentation of mRNA-based and virus-vectored SARS-CoV-2vaccines", Vaccines(Basel), 9, pp.848~ (2021)
- Chan AT, "De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know?", Nephrology (Carlton), 27, pp.5~6 (2022)
- Skeoch S, "Drug-induced interstitial lung disease : a systematic review", J Clin Med, 7, pp.356~ (2018)
- Shimizu T, "Interstitial pneumonitis after COVID-19 vaccination : a report of three cases", Allergol Int, 71, pp.251~253 (2022)
- Kono A, "A case of severe interstitial lung disease after COVID-19 vaccination", QJM, 114, pp.805~806 (2022)
- Matsuzaki S, "COVID-19 mRNA vaccine-induced pneumonitis", Intern Med, 61, pp.81~86 (2022)
- Yoshifuji A, "COVID-19 vaccine induced interstitial lung disease", J Infect Chemother, 28, pp.95~98 (2022)
- Piqueras MB, "Acute eosinophilic pneumonia following mRNA COVID-19 vaccination : a case report", Arch Bronconeumol, 58(Suppl 1), pp.53~54 (2022)
- Stoyanov A, "Delayed hypersensitivity to the Comirnaty coronavirus disease 2019 vaccine presenting with pneumonitis and rash", Ann Allergy Asthma Immunol, 128, pp.321~322 (2022)
- Amiya S, "Case report : acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination", Int J Infect Dis, 116, pp.255~257 (2022)
- Wang T, "Combined myopericarditis and pneumonitis post–Pfizer vaccine against coronavirus disease 2019in a healthy Caucasian middle-aged man", Infect Dis Clin Pract, 30, pp.e1097~ (2022)
- Miqdadi A, "Acute eosinophilic pneumonia associated with the anti-COVID-19 vaccine AZD1222", Cureus, 13, pp.e18959~ (2021)
- Collard HR, "Acute exacerbation of idiopathic pulmonary fibrosis : an International Working Group Report", Am J Respir Crit Care Med, 194, pp.265~275 (2016)